We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
GPhA is stepping up its opposition to the FDA’s proposed generics labeling rule, releasing a survey that shows more than half of physicians, physician assistants and pharmacists would find the new system confusing for them and their patients. Read More
Top Republican lawmakers want the Obama administration to examine whether the FDA has the authority to impose a generic drug labeling rule, ratcheting up the rhetoric in an increasingly political battle over the controversial measure. Read More
Generic drugmaker Mylan agreed to pay Abbott Labs $5.3 billion in stock to acquire part of its international generic drug business in a deal that vastly spreads the geographic reach of the Pennsylvania-based firm. Read More
Indian pharmaceutical authorities have enacted price controls on scores of branded-generic drugs to treat diabetes and cardiovascular disorders, a decision that one industry observer warns will also have a chilling effect on the introduction of patented drugs into the country as branded companies worry that price controls may soon come to their sector as well. Read More
Canadian pharmaceutical company Duchesnay has filed a lawsuit against generic manufacturer Actavis over its challenge to Duchesnay’s morning sickness drug Diclegis. Read More
Salix Pharmaceuticals has convinced the FDA to reverse its 2012 stance blocking the company’s sNDA for an expanded use of its opioid-induced constipation drug Relistor. Read More
Iowa’s Supreme Court once again confirmed that brand manufacturers can’t be held liable for injuries sustained when patients take a generic version of their drug. Read More
Colorado-based Allos Therapeutics and three research organizations are suing Dr. Reddy’s over its proposed generic version of the brand manufacturer’s orphan lymphoma drug Folotyn. Read More